Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 73Breast 73Gastrointestinal 53CNS 35Endocrine 32Lymphoid 30Head & Neck 24Tumor-Agnostic 19Other hematologic neoplasm 19NET 19Dermatologic 18Thoracic 17Other solid neoplasm 17Gynecologic 17Sarcoma 15Plasma cell 11Myeloid 5Other neoplasm 1Other 1Classical hematology 1

Conditions

Somatostatinoma 1Mucositis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Renal Cell 1Carcinoma, Islet Cell 1Breast Neoplasms 1

Interventions

Exercise 27Metformin 20Surveys and Questionnaires 19Methods 14Educational Status 12Early Intervention, Educational 11Counseling 11Tirzepatide 9Standard of Care 9Nutrition Assessment 9Diet Therapy 9Resistance Training 8Radiotherapy 8Diet 8Interviews as Topic 7Liraglutide 6semaglutide 5Radiation 5Low-Level Light Therapy 5Exenatide 5Diet, Mediterranean 5Dexamethasone 5Cryotherapy 5Caloric Restriction 5Blood Specimen Collection 5Bariatric Surgery 5Vitamin D 4Therapeutics 4Sugars 4Specimen Handling 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Everolimus × Other × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡